Lundbeck and Takeda take on Lupin over anti-depressant ANDA

Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Takeda makes fourth offer to buy Shire

23 April 2018 Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

Americas

Takeda and Lundbeck take more patent action over Trintellix

12 June 2018 Drug makers Takeda and Lundbeck have filed a patent infringement lawsuit over anti-depressant medication Trintellix (vortioxetine hydrobromide), less than a month after launching similar claims.

Biotechnology

Lundbeck to acquire Abide Therapeutics for $250 million

8 May 2019 Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.

More on this story

Asia-Pacific

Takeda makes fourth offer to buy Shire

23 April 2018 Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

Americas

Takeda and Lundbeck take more patent action over Trintellix

Biotechnology

Lundbeck to acquire Abide Therapeutics for $250 million

8 May 2019 Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.

More on this story

Asia-Pacific

Takeda makes fourth offer to buy Shire

23 April 2018 Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

Americas

Takeda and Lundbeck take more patent action over Trintellix

Biotechnology

Lundbeck to acquire Abide Therapeutics for $250 million

8 May 2019 Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.